11β Hydroxysteroid dehydrogenase – 1 activity in type 2 diabetes mellitus: a comparative study

Ravindra Shukla 1*, Asish Kumar Basu 2, Biplab Mandal 2, Pradip Mukhopadhyay 3, Animesh Maity 2, Satyam Chakraborty 2 and Praveen Kumar Devrabhai 2

Abstract

**Background:** A comparative study of 11β HSD 1 activity in type 2 diabetes mellitus subjects with respect to fasting blood glucose and other metabolic parameters was conducted.

**Methods:** A case control experimental study was performed enrolling thirty type 2 diabetes mellitus patients and thirty age, gender and BMI matched controls using cortisone acetate test.

**Results:** The rise of serum cortisol after oral 25 mg cortisone acetate from baseline (dexamethasone suppressed level) is higher in subjects with type 2 diabetes and is associated with exercise, BMI, SGOT but not daily calorie intake, lipid parameters and thyroid status. Fasting blood glucose after overnight 1 mg oral dexamethasone is a strong predictor of 11HSD1 activity, irrespective of presence of type 2 diabetes.

**Conclusion:** 11β HSD 1 activity is higher in type 2 diabetes mellitus subjects, especially those who are lean. Future 11 β HSD 1 inhibitors targeting metabolic syndrome, will be most useful in those with increased fasting blood glucose. The role of DHEAS and vitamin D status needs to be explored.

**Keywords:** 11 β HSD 1, Type 2 diabetes mellitus, Cortisone acetate test

Background

The enzyme 11 β HSD is a bi-functional enzyme with activity dependent on NAD(H)/NAD ratio. Type 1 activity of 11βHSD implies cortisone (E) to cortisol (F) conversion. Cortisol generated by 11βHSD1 in hepatocytes can increase hepatic glucose output by activating transcription of phosphoenol pyruvate kinase (PEPCK). This increase in hepatic glucose output occurs independent of any interaction with insulin, glucagon or free fatty acids (FFA) [1]. Transgenic mice over expressing 11βHSD1 develop metabolic syndrome but not obesity. This has lead to the hypothesis that type 2 diabetes mellitus is a form of localized Cushings syndrome [2]. This experimental study compares 11 β HSD1 activity between type 2 diabetes mellitus patients and healthy controls. This study also correlates 11βHSD1 activity with various metabolic parameters in each group. We devised a unique protocol of cortisone acetate test to estimate 11βHSD1 activity. The test has been described previously [3].

Methods

The study was carried out in 2014–2015 and Test protocol as described below was approved by Institutional Ethics Committee (IEC) of Kolkata Medical College, India. The objective was to assess 11βHSD1 activity in cases and compare it with healthy controls. Thirty subjects with type 2 diabetes and thirty healthy controls were selected for the study. Cases were selected from those attending outpatient services of Department of Endocrinology Medical College Kolkata, while healthy controls were selected from those volunteering for the study. The sample size calculated using formulae:

\[ \text{Sample size} = Z \times \text{S.D.}/d^2 \]

\[ Z = \text{standard normal variate at } 1.96, \]

\[ \text{S.D.} = 4.5 \mu g/dl \text{ based on pharmacokinetic absorption data of cortisone acetate.} \]
$d = \text{precision} = 3 \text{ based on previous study on type 1 DM [3]}$. Those with known diabetic complications and HbA1c > 7 mmol/l or random blood glucose > 200 mg/dl in preceding 7 days were excluded. Healthy subjects were chosen to those volunteering for the study.

**Cortisone acetate test protocol**

All subjects were admitted a day before testing and were given 1 mg dexamethasone at 11 pm. Next day, 8:00 am fasting blood glucose and serum cortisol sample was taken. Thereafter, tablet cortisone acetate (25 mg) was given with standardized breakfast of two brown bread slices. Second sample of serum cortisol was taken at 8:45 am. The difference between the cortisol values was denoted as delta cortisol. Delta cortisol is taken as surrogate of $11\beta$HSD1 activity.

Roche COBAS e411 (Co-efficient of variation < 10%) was used for measurements of serum cortisol, TSH, free T4, TT4, 25(OH) vitamin D. CENTAUR was used for lipid profile and other investigations. NHAMS and NIN-ICMR guidelines were followed for anthropometry and daily dietary calorie calculation, respectively. Physical activity, BMI, and calorie intake was categorized (see Additional file 1). Kolmogorov-Smirnoff and Shapiro Wilk tests were used to check normality. Students t test, one way & two way ANOVA, Mann-Whitney U test, Friedmen test, Kruskal Wallis tests were used for in between groups comparison. Wilcoxon Signed Rank test was used to compare pre & post dexamethasone fasting blood glucose. The Pearson & Spearmen test was used to test association between variables. A multiple regression analysis model was used to find out various parameters affecting delta cortisol activity. SPSS software version 20 was used for statistical analysis.

**Results**

Study subjects were well matched for age & weight (Table 1). Metabolic parameters were compared using t-test and Mann-Whitney test as described in Table 2. All subjects (except one diabetic subject) had dexamethasone suppressed cortisol level < 1.8 mcg/dl. There was no statistically significant difference between diabetic and non diabetic subjects in 8:00 h serum cortisol level. ($p = 0.211$, Mann-Whitney test) (Table 3). The $11\beta$ HSD1 activity in diabetes subjects was found to be significantly increased ($p = 0.022$, Mann-Whitney test) as compared to controls (Table 3).

In study subjects < 35 years of age, $11\beta$ HSD1 activity was significantly increased in diabetics as compared to healthy controls (Table 4, Fig. 1) ($p = 0.005$, Mann-Whitney test). In other age groups, $11\beta$ HSD1 activity was not statistically different between diabetics and controls (Table 4, Fig. 1). Similarly, in subjects who exercise > 180 min/week, $11\beta$ HSD1 activity was found to be significantly more in diabetics (Table 4, Fig. 2) ($p = 0.004$, Mann-Whitney test). Diabetes subjects with BMI < 23 kg/m2 had significantly higher $11\beta$ HSD1 activity as compared to healthy controls (Table 4) ($p = 0.017$, Mann-Whitney test). There was no effect of calorie intake on $11\beta$ HSD1 activity (Table 4, Fig. 3).

$11\beta$ HSD1 activity was inversely associated with waist circumference ($p = 0.027$, $\rho = -0.356$, Pearson’s correlation) in diabetics, albeit weakly. SGOT was significantly increased in diabetes and was strongly associated with $11\beta$ HSD1 activity in diabetes subjects (spearman $\rho = 0.638$, $p = 0.002$). Fourteen diabetes subjects had finding of fatty liver on sonography. Post dexamethasone FBG was significantly raised in subjects with diabetes ($p = 0.01$, Wilcoxon Signed Rank test) but not healthy controls. $11\beta$ HSD1 activity was strongly correlated with post dexamethasone FBG in both cases and controls. Even after adjusting for increased FBG in diabetics, post dexamethasone FBG correlated with delta cortisol. Curiously, the same association was not observed with pre dexamethasone FBG. LDL was significantly associated with $11\beta$ HSD1 activity in healthy controls but not diabetics.

$11\beta$HSD1 activity was analysed separately in diabetes and healthy participants using Spearman correlation (Table 5). In diabetics, $11\beta$HSD1 activity was found to be associated with SGOT ($p = 0.02$), alkaline phosphatase (ALP) ($p = 0.03$), FBG ($p = 0.008$). In healthy subjects, it was found to be associated with systolic blood pressure ($p = 0.013$), LDL ($p = 0.006$), triglycerides. Age, BMI, TSH and daily calorie intake had no effect on $11\beta$HSD1 activity. Multiple regression analysis was performed to predict $11\beta$ HSD1 activity using automatic linear modeling, with $11\beta$ HSD1 activity being taken as outcome variable using forward stepwise model building method. Five variables were identified at $p < 0.05$ (Table 6).

| Table 1 Characteristics of Diabetes and Healthy controls cases and control | Diabetes | Healthy controls |
|-----------------------------|----------|------------------|
| Age (yrs)                  | Mean     | Mean             |
| Daily average calorie intake(kcal) | 1876    | 2172             |
| Height                      | 1.56     | 1.57             |
| Weight                      | 62       | 61               |
| Body mass index (kg/m2)     | 25.25    | 24.65            |
| Waist circumference (cm)    | 89       | 83               |
| Systolic BP (mm of Hg)      | 137      | 125              |
| Diastolic BP(mm of Hg)      | 78       | 75               |

Subjects were well matched in mean age, BMI and waist circumference. Age range was (32 years –62 years) and (20 years – 64 years) in cases and control respectively. Diabetics had lower total calorie intake and higher systolic blood pressure. Mann-Whitney test was used for comparison.
Discussion

Cortisone acetate test has been previously described for measuring 11βHSD1 activity [3]. We added overnight dexamethasone suppression, so as to bring 0800 h basal cortisol at similar levels in the study subjects. It has been shown that serum cortisol levels attained 45 min after cortisone acetate ingestion is entirely due to 11βHSD1 activity [4]. Hence, endogenous cortisol secretion acting as confounder, is ruled out. Delta cortisol can thus be used as surrogate marker of 11βHSD1 activity in splanchnic circulation, more specifically liver [5].

Increased 11βHSD activity could lead to development of metabolic syndrome [6]. 11β HSD knock off transgenic mice have higher insulin sensitivity. They are also resistant to develop metabolic syndrome when put on high fat diet [7]. An 11βHSD1 inhibitor has been shown to reverse metabolic syndrome in mice over expressing 11βHSD1 [8]. This has lead to the hypothesis that increased 11βHSD1 activity has a contributory role in development of type 2 diabetes/metabolic syndrome. A study carrying out cortisone acetate test in young type 1 diabetes subjects reported decreased 11βHSD1 activity and inverse correlation was found with insulin dose [4]. Insulin directly inhibits 11βHSD1 activity in liver [9]. Insulin resistance would similarly increase 11βHSD1 activity. It would be imperative to compare our results with those studies that evaluated 11βHSD by other methods e.g. Urinary tetrahydrocortisol (THF) + allo-THF: tetrahydrocortisone (THE) ratio [10]. An increased ratio means relative decrease in cortisol inactivation i.e. increased 11βHSD1. Studies using (THF + allo-THF): THE ratio have not found any difference with respect to type 2 DM [11] except one [12]. However, the method of using

Table 2  Fasting lipid profile, liver & renal function tests of the study subjects

| Lipid profile by automated analyser or ELISA method. All other tests by ELISA | cases and control | p-value |
|---|---|---|
| | diabetes | Mean | Standard Deviation | healthy controls | Mean | Standard Deviation |
| total cholesterol (mg/dl) | 171 | 35 | 185 | 42 | 0.84 |
| LDL (mg/dl) | 107 | 30 | 120 | 27 | 0.08 |
| HDL (mg/dl) | 41 | 10 | 41 | 10 | NS |
| Total triglyceride (mg/dl) | 151 | 50 | 143 | 49 | 0.65 |
| Total bilirubin (mg/dl) | 1.0 | .4 | 9 | .1 | 0.4 |
| SGOT (U/L) | 41 | 16 | 34 | 20 | 0.029 |
| SGPT (U/L) | 36 | 14 | 31 | 11 | 0.20 |
| S. Albumin (U/L) | 4.5 | .7 | 4.7 | .4 | 0.069 |
| S.Globulin (U/L) | 3.3 | .6 | 3.0 | .0 | 0.07 |
| Alkaline phosphatase | 163 | 62 | 103 | 67 | 0.01 |
| S.creatinine (mg/dl) | .9 | .1 | .9 | .1 | NS |
| 25 (OH) vitamin D | 18.4 | 7.4 | 23 | 12.3 | 0.021 |

Mann-Whitney test was done for non-parametric variables (Bilirubin, SGOT<SGPT,Albumin, Globulin, creatinine, 25(OH) vitamin D) 

Table 3  Hormonal evaluation of study subjects

| Delta cortisol is difference in S.cortisol levels before and 40 min after Tablet cortisone acetate 25 mg PO | cases and control | p-value |
|---|---|---|
| Diabetes | Healthy controls | |
| Mean | Standard Deviation | Mean | Standard Deviation | |
| TSH (mU/L) | 2.65 | 1.18 | 2.36 | 1.13 | 0.11 |
| free T4 (ng/dl) | 1.2 | .3 | 1.1 | .2 | 0.01 |
| Fasting blood glucose (mg/dl) | 150.43 | 40.39 | 83.37 | 7.80 | < 0.01 |
| 8 am cortisol (mcg/dl) | 129 | 21.9 | .84 | .46 | 0.211 |
| 8 40 am cortisol (mcg/dl) | 13.58 | 10.38 | 7.52 | 7.24 | 0.012 |
| delta (8 40–8 00 am cortisol) | 12.29 | 10.65 | 6.68 | 7.24 | 0.022 |

Mann-Whitney test used to compare values in diabetics and healthy control

Diabetics had higher mean Fasting blood glucose(FBG), TSH & cortisol values
The cortisol-allo-THF ratio has an inherent fallacy. The cortisol-allo-THF ratio is likely affected by differences in 5α/5β reductase enzyme activities and this can lead to erroneous conclusion [12]. One study using cortisone acetate test to estimate 11βHSD1 activity in type 2 diabetes found it to be decreased, but baseline cortisol was not suppressed [6]. Studies examining 11βHSD activity in diabetes patients by 11βHSD1 mRNA in skeletal tissue have found it to be increased in diabetes [13]. Previous report of decreased post dexamethasone 900 h cortisol as compared to controls [6] has not been confirmed in our study, possibly because we used 1 mg instead of 0.25 mg dexamethasone.

In humans, the 11β HSD1 activity differs with age. Cortisone acetate is ineffective in treating congenital adrenal hyperplasia (CAH) in children less than 2 years of age, suggesting decreased 11βHSD1 activity in younger age [14]. Growth hormone (GH) inhibits 11βHSD1 and with decreasing GH levels, 11β HSD1 activity is increased in elderly [15]. 11βHSD1 activity was compared in three age groups: < 35 years, 35–50 yrs., > 50 yrs.

These groups were determined in taking into consideration DHEAS levels, which vary greatly in age groups defined above. DHEAS is an inhibitor of 11βHSD1 enzyme in human adipocytes in vitro [16]. In age group < 35 years, diabetics had higher 11βHSD1 activity as compared to healthy individuals. This was not due to duration of diabetes, as there was no significant difference in 11βHSD1 activity with diabetes duration. DHEAS levels are higher in young adults and decline precipitously in third decade (so called adrenopause). We speculate that decreased DHEAS levels/premature adrenopause has lead to increased 11βHSD1 activity in diabetics < 35 years of age. As there is no precedent study examining 11βHSD1 with DHEAS, the matter cannot be concluded. 11βHSD1 in vivo shows sexual dimorphism with males having higher higher activity [17]. We did not find any difference, possibly due skewed gender distribution of study subjects.

**Effect of exercise**

11βHSD1 activity was significantly increased in those diabetes subjects, who exercise as compared to healthy subjects with same range of physical activity. However, in those with sedentary or lower level of physical activity, no difference in 11βHSD1 activity was observed. Acute intense physical activity leads to increased 11βHSD1 activity [18]. The effect of chronic physical activity on 11βHSD1 has been less adequately studied. Chronic physical exercise induces Nuclear Factor kappa B (NFkB) activation and increased transcription in adult males [19]. NFkB has been found to induce 11βHSD1 activity under hypoxic conditions [20]. Increased cellular hypoxia can thus lead to increased 11βHSD1 activity. Exercise induces hypoxia in skeletal muscle due to increased demand for ATP. It can be therefore hypothesized that diabetic subjects had ‘maladapted’ cellular energetics leading to increased 11β HSD1 activity on > 180 min/week of exercise. Increased mitogenesis of arterial smooth muscle cell is a feature of insulin resistance. It is accompanied by increased NFkB activity and higher SBP [21]. Diabetic subjects who exercised had increased systolic blood pressure (SBP) as compared to controls. This paradox of increased blood pressure with exercise can be explained by NFkB induced 11β HSD1 activity.

Both BMI and waist circumference were well matched in cases and controls. Diabetes subjects with normal weight (i.e < 23 kg/m2) were found to have significantly higher 11β HSD1 activity not only compared to controls, but also compared with those diabetics with BMI > 23 kg/m2. As no standards for ‘normal’ delta cortisol exist, the above statement could mean decreased 11β HSD1 activity in healthy subjects rather than increased activity in diabetics. Indeed decreased 11β HSD1 activity has

| Table 4 | Comparison of delta cortisol in diabetes subjects and control |
|---------|---------------------------------|
| factor  | Delta cortisol Cases (mcg/dl)  | Delta cortisol control (mcg/dl) | P value |
| Age (n) | < 35 (20)  | 13 | 5.4 | 0.005  |
| | 35–50 (31) | 12 | 9 | 0.08  |
| | > 50 (08) | - | - | -  |
| BMI (n) | < 23 (19) | 14.2 | 8.9 | 0.017  |
| | 23–27 (29) | 11.3 | 9.1 | 0.142  |
| | > 27 (12) | 9 | 8.2 | 0.755  |
| Physical activity(n) | Sedentary (15) | 16 | 11 | 0.06  |
| | Intermediate(18) | 13.4 | 10.2 | 0.083  |
| | Exercise (27) | 15.1 | 6.2 | 0.004  |
| Calorie intake | < 1600 (8) | 11.2 | 6.1 | 0.052  |
| | 1600–1900 (18) | 12.3 | 8.2 | 0.08  |
| | 1900–2200 (21) | 12 | 8.2 | 0.03  |
| | 2200–2500 (7) | 9 | 8.4 | 0.3  |
| | > 2500 (6) | 8 | 8.3 | 0.24  |

Mann-Whitney test was used to compare delta cortisol between cases and control as shown above.

Delta cortisol was increased in diabetics as compared to healthy controls and was statistically significant in those subjects < 35 years of age (p = 0.005), BMI < 23 (p = 0.017) and in those who exercise (p = 0.004).

When delta cortisol was compared in various calorie groups, it was significantly more in diabetics. However, when Kruskal Wallis test applied, the difference was not significant. Also see Fig. 3.
been postulated as an adaptation to protect from adverse metabolic effect of obesity in Zucker diabetic rats [22] and possibly in humans [11]. Those who fail to downregulate 11βHSD1 activity develop diabetes, hypertension and dyslipidemia. Decreased 11βHSD1 activity might protect healthy controls from diabetes. However, this adaptation was lost at BMI > 23. At BMI greater than 23, 11βHSD1 activity was similar in cases and control. This indicates that after a certain degree of obesity (which in our population is BMI > 23), other factors i.e. insulin resistance take precedence in causation of diabetes, hypertension and dyslipidemia. Atleast one selective 11 β HSD1 inhibitor has entered phase 3 trial [23]. On basis of this study,a hypothetical target group for 11 β HSD1 inhibitor would be those with BMI < 23 kg/m2 - The “thin fat Indian” phenotype.

Waist circumference was inversely correlated with 11βHSD1 activity in diabetes i.e. increased waist circumference was associated with decreased 11 β HSD1 activity. Waist circumference represents visceral adipose tissue (VAT) more closely. The VAT has almost exclusively cortisol (F) to cortisone(E) conversion (i.e. 11β HSD2 activity). As a result the substrate cortisone (E) is generated through VAT is presented to liver for localized cortisol generation [5]. 11 β HSD, too, is located around portal venules in the liver [24]. However in subjects with higher VAT, there is relative increase in 11β HSD1 activity of visceral fat and decrease in liver 11 β HSD1 activity. This “compensatory” decrease in liver 11βHSD1 activity is what our test measured. It could be due to adipokines [6]. In those with gynoid fat distribution visceral tissue 11βHSD1 is decreased [25].

Both systolic and diastolic blood pressure was associated with increased 11 β HSD1 activity in controls but not in diabetics, possibly because of confounding effect of anti-hypertensives. Cortisol- cortisone shuttle regulated by 11 β HSD1 activity plays role in increased vascular tone, more so in clinical states of primary aldosteronism (where diastolic hypertension is prominent) and Cushing syndrome [26]. Mice over expressing 11βHSD1 have severe hypertension due to increased angiotensinogen generation by the liver [27]. Our study finds the association for the first time in normotensive healthy adults.

Two FBG values were available for each patients. Matching FBG could not be possible in two groups. Dexamethasone significantly increased FBG in diabetic patients but not healthy controls. 11 β HSD1 activity was strongly associated with FBG in both cases and
control. Linear modeling showed that even after adjusting for the presence of diabetes, post dexamethasone FBG was associated with increased 11β HSD1 activity. The same association was not found with pre dexamethasone FBG. This points to a possible influence of dexamethasone itself on 11βHSD1 activity. Dexamethasone has been shown to induce 11β HSD 1 gene transcription both directly and indirectly. Direct action takes days, while indirect action takes minutes to manifest. Indirect action occurs by binding to P2 promotor region, located upstream to HSD11B1 gene [28, 29].

LDL was well matched in cases and controls. But only in healthy subjects, 11 HSD1 activity was associated with LDL. We attribute lack of association of 11 β HSD1 activity with LDL in diabetes subjects to concomitant statin use. Since statins suppress low grade inflammation of chronic diseases, they could well have inhibitory effect on 11 β HSD1 activity. We could not relate 11β HSD1 activity with triglycerides. Glucocorticoids increase total cholesterol, LDL, HDL, but major increase is in triglycerides [30].Thus, there is diversion between glucocorticoid (GC) receptor action and 11βHSD1 activity on lipid metabolism. This can be explained by non-genomic action of glucocorticoids on TG synthesis pathway, circumventing 11 β HSD enzyme. NAFLD is widely considered as hepatic manifestation of metabolic syndrome. Previous studies have documented derangement of cortisol metabolism, i.e. increase localized liver glucocorticoid action [31]. Systemic hypercortisolemia of Cushings disease ironically protects from hepatic steatosis, and glucocorticoids have therapeutic benefit in alcoholic hepatitis. Altered 11βHSD1 activity might be one of the reason [32]. SGOT was strongest predictor of 11 β HSD1 activity on multiple regression. Since SGOT/SGPT ratio is increased in non alcoholic steatohepatitis (NASH), we speculate role of 11 β HSD1 activity as determining factor in fatty liver to NASH progression.

Although serum alkaline phosphatase (ALP) was significantly increased in diabetics, no association with 11 β HSD1 activity was found after multiple regression. The 11β HSD1 activity is present in both osteoclasts and osteoblasts. Invitro studies have shown increased 11 β HSD1 activity to be associated with bone reabsorption markers including ALP [33]. Firstly, increased ALP levels in diabetics can be due to more prevalent vitamin D deficiency [34, 35].Secondly, although ALP is bone turnover marker and bone turnover markers are associated with 11βHSD1 activity, it is premature to draw any conclusion in the absence of other bone turnover markers. Thirdly, increased ALP in diabetics who undertake rigorous physical activity might be due to subtle trauma,
microfractures and osteoarthritis. Fourthly, the test was not for bone specific ALP. TSH was evaluated in the two the groups and no significant association was found with 11βHSD1 activity.

**Conclusion**

We compared 11β HSD1 activity in type 2 diabetes subjects with healthy controls using a novel protocol of cortisone acetate test. 11βHSD1 activity is increased in type 2 diabetes mellitus, those with diabetics with BMI < 23 kg/m², and those who engage in regular exercise. It is also associated with hepatic enzyme elevation, systolic blood pressure and possibly with DHEAS and vitamin D deficiency. There exists a dichotomy between glucocorticoid action and 11β HSD1 activity in lipoprotein metabolism. Fasting blood glucose, especially after overnight dexamethasone is a strong determinant of 11β HSD1 activity and can be used as its surrogate marker. Future 11βHSD1 inhibitors targeting metabolic syndrome will be most useful in those with increased fasting blood glucose.

**Table 5** Delta cortisol analysed separately for cases and control

| Variable | Case p-value | Controls p-value |
|----------|--------------|-----------------|
| SBP      | 0.235        | 0.013           |
| DBP      | 0.101        | 0.007           |
| LDL      | 0.113        | 0.006           |
| Triglycerides | 0.8 | 0.6 |
| FBG      | 0.008        | 0.02            |
| Alkaline Phosphatase | 0.03 | 0.4 |

SBP, DBP, LDL, Triglycerides, FBG, Alkaline phosphatase was analysed for correlation with 11 β HSD 1 activity in diabetics (1st column). Spearman correlation was used.

**Table 6** Results of linear regression using automated linear model

| Variable          | Coefficient | Importance | Significance |
|-------------------|-------------|------------|--------------|
| FBG               | 0.164       | 0.502      | 0.000        |
| SGOT              | 0.194       | 0.149      | 0.007        |
| Pre FBG           | 0.206       | 0.018      | 0.018        |
| SGPT              | 0.231       | 0.026      | 0.026        |
| 1 ÷ vitamin D     | 0.230       | 0.023      | 0.033        |

The model assumes delta cortisol to be gold standard of 11 β HSD1 activity. 5 variables were identified at p < 0.05. -FBG, SGOT, pre dexa FBG, SGPT and inverse of total 25 (OH) vitamin D. At p < 0.1 systolic blood pressure was also identified as predicting variable (not shown).
Additional file

**Additional file 1**: Categorization of study subjects (DOCX 13 kb)

Abbreviations

ALP: Alkaline phosphatase; BMI: Body Mass Index; DHEAS: Dihydroepiandrosterone sulfate; FBG: Fasting blood glucose; HSD: Hydroxysteroid dehydrogenase; NAD (P): Nicotinamide adenine dinucleotide phosphate; NAD: Nicotinamide adenine dinucleotide; NAFLD: Nonalcoholic fatty liver disease; NFκB: Nuclear Factor kappab; PEPCK: Phosphoenol pyruvate kinase; SGOT: Serum Glutamate oxaloacetate transferase; SGPT: Serum Glutamate Pyruvate Transf erase; TG: Triglycerides; THE: Tetrahydrocortisone; THF: Tetrahydrocortisol; TSH: Thyroid Stimulating Hormone; VAT: Visceral Adipose Tissue; WC: Waist circumference

Acknowledgements

The authors thank RSSDI for grant of 50000 INR for logistics of the project. The fund was used towards purchase of serum cortisol kit for the project.

Consent to participate

Study participants gave written consent to participate and publish.

Funding

This project was partially funded by Research Society for study of Diabetes(RSSDI) in India grant as acknowledged below. The RSSDI had no role in study design, collection, analysis, interpretation, and writing of manuscript.

Availability of data and materials

Raw dataset to be made available on request to corresponding author in excel file.

Authors’ contributions

RS hypothesized, designed study and wrote manuscript. AB & BM made critical revisions in discussion, interpretation and conclusion and thus helped in writing the manuscript. PMB & SC helped with data research. PD, AM helped in test standardization. All authors have read and approved the final manuscript.

Competing interest

The authors disclose that there is no conflict of interest financial or otherwise with regard to the study.

Ethics approval and consent to participate

The study was approved by Independent Ethics Committee (IEC) of Medical College, Kolkata, India, under West Bengal University of Health Sciences(WBUHS). The ethics committee no is ECR/287/Inst/WB/2013/RR-16.

Consent for publication

Not Applicable. See above.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Endocrinology & Metabolism, AIIMS, Jodhpur 342005, India. 2Medical College, Kolkata, Kolkata, India. 3PGIMER, Kolkata, India.

Received: 16 May 2018 Accepted: 16 January 2019

Published online: 24 January 2019

References

1. Edgerton DS, Basu R, Ramanran C, Farmer TD, Neal D, Scott M, Jacobson P, et al. Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog. Am J Physiol Endocrinol Metab. 2010 May;298(5):E1019–26.
2. Paterson JM, Morton NM, Flevet C, Holmes MC, Staels B, Holmes MC, et al. Metabolic syndrome without obesity: hepatic over expression of 11β-

3. Šmunková HR, Hill M, Kriz L, Vrbkova J, Kvasnickova H, Vondra K. Evaluation of hepatic 11 β-Hydroxysteroid dehydrogenase activity by cortisone acetate test in young adults with diabetes mellitus Type1. Physiol Res. 2011;60:263–70.
4. Andrew R, Smith K, Jone GC, Walker BR. Distinguishing the activities of 11 β-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol radio tracer. J Clin Endocrinol Metab. 2002;87:277–85.
5. Basu R, Singh RJ, Basu A, Chittlapilly EG, Johnson CM, Toffolo G, et al. Splanchnic cortisol production occurs in humans — evidence for conversion of cortisone to cortisol via the 11-beta-hydroxysteroid dehydrogenase type 1 pathway. Diabetes. 2004;53:201–9.
6. Roberts C, Andrew S, Olive H, Dawn EWL, Ruth A, Walker BR. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endo Metab. 2002;87(13):5587–93.
7. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, et al. 11 β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resistant hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A. 1997;94:14924–9.
8. Hermannowksi-Vosatk A, Balkovec JM, Chent K, Cheng HY, Hernandez M, Koo GC, et al. 11Beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med. 2005;202:17–27.
9. Putignano P, Pecori GF, Cavagnini F. Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome. J Endocrinol Invest. 2004;27:969–74.
10. Palermo M, Shackleton CH, Mantero F, Stewart PM. Urinary free cortisol and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol. 1996;45:605–11.
11. Kerstens MN, Remens SC, Sluter WJ, Pratt JJ, Wothers BG, Dullaart RP. Lack of relationship between 11β-Hydroxysteroid dehydrogenase set point and insulin sensitivity in the basal state and after 24 h of insulin infusion in healthy subjects and type 2 diabetic patients. Clin Endocrinol. 2000;52:403–11.
12. Agha A, Monson JP. Modulation of glucocorticoid metabolism by the growth hormone-IGF-1 axis. Clin Endocrinol. 2007;66(95):659–66.
13. Abdallah BM, Beck-Nielsen H, Gaster M. Increased expression of 11 beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Increased expression of 11 beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur J Clin Invest. 2005;35(10):627–34.
14. Jinn K, Sakusa N, Normura S, Fujitaka M, Ueda K, Kihara M. Failure of cortisone acetate therapy in 21-hydroxylase deficiency in early infancy. Pediatr Int. 2001;43:478–82.
15. Toogood AA, Taylor NF, Shalet SM, Monson JP. Sexual dimorphism of cortisol metabolism is maintained in elderly subjects and is not estrogen dependent. Clin Endocrinol. 2000;52:61–6.
16. McNelis JC, Manopolouos KN, Gathercole LL, Bujalska IJ, Stewart PM, Tomlinson JW, AH W. Dehydroepiandrosterone exerts anti glucocorticoid action on human adipocyte proliferation, differentiation, and glucose uptake. Am J Physiol Endocrinol. 2003;305:e134–44.
17. Raven PW, Taylor NF. Steroid metabolism in healthy men and women. J Endocrinol. 1995;147(Suppl. 2):100.
18. Dovia A, Roveda E, Sciolla C, Montauril A, Raffaeli A, Saba A, et al. Intense physical exercise increases systemic 11beta-hydroxysteroid dehydrogenase type 1 activity in healthy adult subjects. Eur J Appl Physiol. 2010;108(6):681–7.
19. Vider J, Laaskonen D, Kilk J, Lehtmaa J, Zilmer M, et al. Physical exercise induces activation of NF-κB and IGF-1 axis. Clin Endocrinol. 2007;66(95):659–66.
20. Vider J, Laaskonen D, Kilk J, Atalay M, Lehtmaa J, Zilmer M, et al. Evidence for conversion of cortisone to cortisol via the 11-beta-hydroxysteroid dehydrogenase type 1 pathway. Diabetes Care. 2010;33:1516–22.
24. Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM. Immunohistochemical localization of type 1 11β-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab. 1998;83:1325–35.

25. Stewart PM, Boulten A, Kumar S, Clark P, Shackleton C. Cortisol metabolism in human obesity: impaired cortisone to cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab. 1999;84:1022–7.

26. Walker BR, Connacher AA, Webb DJ, Edwards CR. Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man. Clin Sci. 1992;83:171–8.

27. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinya H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest. 2003;112:85–90.

28. Rajan V, Edwards CR, Seckl JR. 11 beta-Hydroxysteroid dehydrogenase in cultured hippocampal cells 11-dehydrocorticosterone, potentiating neurotoxicity. J Neurosci. 1996;16:65–70.

29. Seckl JR, Chapman KE. A novel promoter for the 11beta-hydroxysteroid dehydrogenase type 1 gene is active in lung and is C/EBP alpha independent. Endocrinology. 2006;147:2879–85.

30. Marais AD. Lipids, lipoprotein metabolism and their derangements. Heart. 2005;2(3):18–18.

31. Gastaldelli A. Fatty liver disease: the hepatic manifestation of metabolic syndrome. Hypertens Res. 2010;33:546–7.

32. Tarantino G, Finelli C. Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease. World J Gastroenterol. 2013;19(40):6735–43.

33. Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M, Stewart PM. Expression and functional consequences of 11β-Hydroxysteroid dehydrogenase activity in human bone. Bone. 2000;27:375–81.

34. Dutta D, Maisnam I, Shrivastava A, Sinha A, Ghosh S, Mukhopadhyay P, et al. Serum vitamin-D predicts insulin resistance in individuals with prediabetes. Indian J Med Res. 2013;138:853–60.

35. Maxwell DB, Fisher EA, Ross-Clunis HA 3rd, Estep HL. Serum alkaline phosphatase in diabetes mellitus. J Am Coll Nutr. 1986;5(1):55–9.